A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...
You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's al…
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
The Economist11d
It’s not just AI. China’s medicines are surprising the world, too
In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift ...
Chinese company's drug beats world's biggest-selling medicine: media
A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...
FierceBiotech3d
Pfizer to test Summit's white-hot bispecific with ADCs
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Wall Street Journal1d
Akeso Inc.
1 Day AKESF 7.54% DJIA 0.47% S&P 500 0.84% Health Care/Life Sciences -0.41% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
CNN6d
Just like AI, China’s biotech is disrupting the world. Is the US ready?
How to craft the perfect maternity leave out of office message ...
Medindia13d
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Ra and ST2 for Respiratory and Skin Diseases
HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...
finanzen3d
Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings
Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...
Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...